Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624500 | 0.84 | MMP1 (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL804701 | 0.82 | TSHR (0.33) | TSHRHPGDSMN1; SMN2 | |
| SCHEMBL17548904 | 0.80 | HPGD (0.30) | HPGDSMN1; SMN2 | |
| SCHEMBL26948072 | 0.78 | TSHR (0.36) | L3MBTL1MAPTTSHR | |
| SCHEMBL29810633 | 0.78 | TSHR (0.37) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL271918 | 0.78 | — | — | |
| SCHEMBL2608669 | 0.78 | LMNA (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL7110445 | 0.78 | LMNA (0.40) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL9888822 | 0.77 | MGAM (0.38) | KMT2AL3MBTL1TSHRHPGD | |
| SCHEMBL6381118 | 0.77 | MMP1 (0.33) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322996-A1 | POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE | LIFE TECHNOLOGIES AS (NO) | 2023-10-12 | — | — | US | disclosed |
| US-10004809-B2 | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180092857-A1 | DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TIZIANA LIFE SCIENCES PLC (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| US-20170000740-A9 | COMBINATION THERAPEUTIC NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-01-05 | — | — | US | disclosed |
| US-20160339106-A1 | PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160045445-A1 | COMBINATION THERAPEUTIC NANOPARTICLES | UNIV GEORGIA (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160022835-A1 | Targeted Polymeric Inflammation-Resolving Nanoparticles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160022835-A1 | Targeted Polymeric Inflammation-Resolving Nanoparticles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-8980823-B2 | Formulations of Factor VIIa inhibitors and utility | MOUSA SHAKER A (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130295187-A1 | NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY | MOUSA SHAKER A (US) | 2013-11-07 | — | — | US | disclosed |
| US-8481479-B1 | Formulations of factor VIIa inhibitors and utility | MOUSA SHAKER A (US) | 2013-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004809-B2 | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | SLC25A1, HADHA, CS | MMP1 2643/4885MMP2 1720/4885MMP3 3286/4885 |
| US-20130295187-A1 | NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY | F7, F13B, F5 | MMP1 2147/4885MMP2 603/4885MMP3 2466/4885 |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | MMP1 1468/4885MMP2 2311/4885MMP3 273/4885 |
| US-20180092857-A1 | DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | NPM1, MCL1, MYADM | MMP1 3965/4885MMP2 3426/4885MMP3 2546/4885 |
| US-20160022835-A1 | Targeted Polymeric Inflammation-Resolving Nanoparticles | MRGPRX1, MRGPRX2, CXCL10 | MMP1 156/4885MMP2 1106/4885MMP3 344/4885 |
| US-20170000740-A9 | COMBINATION THERAPEUTIC NANOPARTICLES | ACP3, CASP3, LITAF | MMP1 240/4885MMP2 234/4885MMP3 23/4885 |
| US-20160339106-A1 | PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPY | SLC25A1, HADHA, CS | MMP1 2643/4885MMP2 1720/4885MMP3 3286/4885 |
| US-20160045445-A1 | COMBINATION THERAPEUTIC NANOPARTICLES | ACP3, CASP3, LITAF | MMP1 240/4885MMP2 234/4885MMP3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.